News
Period tracking app Clue provides data for COVID-19 study
De-identified Clue user data used to analyse impact of COVID-19 infections and vaccinations on the menstrual cycle
Berlin-based period tracking app Clue has contributed to a study investigating the impact of Covid infections and vaccinations on the menstrual cycle.
The study, published in Obstetrics & Gynecology, the official journal of the American College of Obstetricians and Gynecologists, was led by Alexandra Alvergne from the University of Montpellier, CNRS and Blair Darney and Alison Edelman from Oregon Health & Science University.
The research is one of the first such studies to use real-time tracked data from an app.
By analysing the recorded menstrual cycle data from over 6,000 Clue users located in 110 countries, researchers determined there is a small, temporary increase in menstrual cycle length following a COVID-19 infection or vaccination.
They found on average, unvaccinated users experiencing a COVID-19 infection reported a 1.45 day increase in menstrual cycle length compared to their previous average cycle length. Vaccinated users reported a similar increase in cycle length following a COVID-19 vaccination.
In both cases, users’ cycle length reverted to the previous average after one cycle, data showed, highlighting that the impact of a COVID-19 vaccination or infection on the menstrual cycle is temporary.
Researchers noted that changes were likely caused by a temporary, disease-related activation of users’ immune systems, although it is challenging to isolate COVID-19 as the sole cause.
Amanda Shea, head of science at Clue, said: “We are proud to contribute to such important research on the effects of COVID-19 on the menstrual cycle and to work closely with world-class researchers at Oregon Health & Science University and the University of Montpellier.
“This research underlines the power of Clue’s de-identified user data and its impact in advancing research into menstrual cycles and reproductive health; benefitting society via a more accurate understanding of reproductive health.”
Alison Edelman, physician scientist at Oregon Health & Science University, said: “Menstrual health is significantly understudied and underrepresented in research and medicine.
“This work is important and necessary to provide answers which can reassure individuals who are experiencing menstrual changes following a COVID-19 infection.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment